Brief: Cleo Diagnostics Says Concluded Design Transfer Activities For Ovarian Cancer Detection Test
12/02/2024 24:44
Feb 12 (Reuters) - Cleo Diagnostics Ltd COV.AX :
* CONCLUDED DESIGN TRANSFER ACTIVITIES RELATING TO CORE
TECHNOLOGY
FOR CO'S OVARIAN CANCER DETECTION TEST
Source text for Eikon: ID:nASX6FCnbc
Further company coverage: COV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CLEO Diagnostics
See all newsAustralia's Cleo Diagnostics jumps after cancer screening test meets milestone
Brief: Cleo Diagnostics Files Patents For Its Ovarian Cancer Screening Test
Australia's Cleo Diagnostics jumps as ovarian cancer test hits validation milestone
Brief: Cleo Diagnostics Receives First Batch Of Commercially Manufactured Test Kits
Brief: Cleo Diagnostics Raises A$5M